Ruth Langholm

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

L. Staudt, A. Rosenwald, T. Greiner, 2012, Blood.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

E. Kimby, M. Karjalainen‐Lindsberg, M. Ehinger, 2008, Blood.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Martin C. Müller, E. Kimby, J. Delabie, 2009, Blood.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

E. Kimby, J. Delabie, M. Karjalainen‐Lindsberg, 2008, Blood.